Impact of hypoglycemic agents on myocardial ischemic preconditioning

Table 1 Effects of hypoglycemic drugs on ischemic preconditioning

Study	Model	Diabetic drug	Effect
Animal studies
Gross et al[23], 1992	Dogs	Glibenclamide (glyburide)	Abolished
Toombs et al[50], 1993	Rabbits	Glibenclamide	Abolished
Mocanu et al[47], 2001	Rats	Glimepiride	Preserved
Maddock et al[51], 2004	Rats	Glibenclamide	Abolished
		Glimepiride	Preserved
Hausenloy et al[61], 2013	Rats	Glimepiride	Preserved
Ye et al[62], 2008	Rats	Pioglitazone	Preserved
		Glibenclamide (glyburide)	Abolished
		Glimepiride	Preserved
Horimoto et al[63], 2002	Rabbits	Glibenclamide	Abolished
		Glimepiride	Preserved
Bose et al[69], 2005	Rats	Native sequenced human GLP-1	Preserved
Zhu et al[73], 2011	Rats	Pioglitazone	IPC mimic
Sasaki et al[74], 2007	Rats	Pioglitazone	IPC mimic
Ahmed et al[75], 2011	Rats	Pioglitazone	IPC mimic
Li et al[76], 2008	Rats	Pioglitazone	Preserved
Wynne et al[77], 2005	Rats	Pioglitazone	IPC mimic
Sarraf et al[78], 2012	Porcine	Pioglitazone	Abolished
		Rosiglitazone	Abolished
Human studies
Cleveland et al[52], 1997	Atrial muscle trabeculae	Glibenclamide (glyburide)	Abolished
Tomai et al[53], 1994	Human	Glibenclamide	Abolished
Klepzig et al[45], 1999	Human	Glibenclamide	Abolished
		Glimepiride	Preserved
Lee et al[54], 2002	Human	Glibenclamide	Abolished
Tomai et al[55], 1999	Human	Glibenclamide	Abolished
Ovünç[56], 2000	Human	Glibenclamide	Abolished
Ferreira et al[57], 2005	Human	Glibenclamide	Abolished
Bilinska et al[58], 2007	Human	Glibenclamide	Abolished
		Gliclazide	Partially preserved
Bogaty et al[59], 1998	Human	Glibenclamide	Preserved
Correa et al[60], 1997	Human	Glibenclamide	Preserved
Loubani et al[64], 2005	Right atrial appendages	Glibenclamide	Abolished
		Gliclazide	Preserved (but abolished in supratherapeutic concentrations)
Hueb et al[66], 2007	Human	Repaglinide	Abolished
Rahmi et al[70], 2013	Human	Repaglinide	Abolished
		Vildagliptin	Preserved

GLP-1: Glucagon-like peptide-1; IPC: Ischemic preconditioning.